Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › valbenazine

valbenazine

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of valbenazine

8 trials tracked of valbenazine: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 69 citations.

8Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 3
  1. Phase 3 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Completed · 69 cited
  2. Phase 3 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed · 7 cited
  3. Phase 4 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed
  4. Phase 4 Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Completed
  5. Phase 4 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Completed
  6. Phase 2 Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed
Show 2 more trials
  1. Phase 2 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Completed
  2. Phase 2 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease
Neurology FDA Approval
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease FDA approves a new sprinkle version of Ingrezza for two movement disorders
The FDA has approved Ingrezza Sprinkle, a VMAT2 inhibitor, for the treatment of adults with tardive dyskinesia and chorea associated with Hu…
FDA approves sprinkle form of Ingrezza to treat involuntary movements in adults with tardive dyskinesia or Huntington's disease chorea.
FDA Apr 10, 2026